SCHEMBL13390983

SCHEMBL13390983

CC(C)Oc1ccc2ccccc2c1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
LMNA P02545 5/20 0.51
NCEH1 Q6PIU2 3/20 0.51
CYP2A6 P11509 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
TP53 P04637 2/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
TLR8 Q9NR97 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11889187 0.82 LMNA (0.46) MAPTCYP1A2CYP2C9CYP2C19LMNA
SCHEMBL3274613 0.81 MAPT (0.62) MAPTCYP1A2CYP2C9CYP2C19NCEH1
SCHEMBL27740253 0.79 MAPT (0.60) MAPTCYP1A2CYP2C9CYP2C19NCEH1
SCHEMBL11807725 0.79 NCEH1 (0.54) MAPTCYP1A2CYP2C9CYP2C19LMNA
SCHEMBL2327449 0.79 MAPT (0.64) MAPTLMNANCEH1CYP2A6SMN1; SMN2
Lonaprofen SCHEMBL29670159 0.78 NCEH1 (0.56) MAPTCYP1A2CYP2C9CYP2C19LMNA
Lonaprofen SCHEMBL2109183 0.78 NCEH1 (0.56) MAPTCYP1A2CYP2C9CYP2C19LMNA
SCHEMBL5610039 0.78 MAPT (0.63) MAPTCYP1A2CYP2C9CYP2C19LMNA
SCHEMBL13323849 0.78 MAPT (0.58) MAPTCYP1A2CYP2C9CYP2C19NCEH1
SCHEMBL28419514 0.78 MAPT (0.58) MAPTCYP1A2CYP2C9CYP2C19NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093747-A1 METHOD OF INDUCING NEGATIVE CHEMOTAXIS CELTAXSYS, INC. 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093747-A1 METHOD OF INDUCING NEGATIVE CHEMOTAXIS PMAIP1, CDC42, DCX MAPT 4842/4885CYP1A2 4827/4885CYP2C9 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.